Familial Chylomicronemia (Type I Hyperlipoproteinemia):治療薬のグローバル治験動向(2014年上半期)...市場調査レポートについてご紹介

【英文タイトル】Familial Chylomicronemia (Type I Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2014

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Familial Chylomicronemia (Type I Hyperlipoproteinemia) 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Europe 9
Top Countries Contributing to Clinical Trials in North America 10
Top Countries Contributing to Clinical Trials in Middle East and Africa 11
Clinical Trials by G7 Countries: Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by Phase 15
In Progress Trials by Phase 16
Clinical Trials by Trial Status 17
Unaccomplished Trials of Familial Chylomicronemia (Type I Hyperlipoproteinemia) 18
Subjects Recruited Over a Period of Time 19
Clinical Trials by Sponsor Type 20
Prominent Sponsors 21
Top Companies Participating in Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials 22
Prominent Drugs 23
Latest Clinical Trials News on Familial Chylomicronemia (Type I Hyperlipoproteinemia) 24
Mar 31, 2014: Isis Reports Final Phase 2 Data On ISIS-APOCIII Rx In Patients With High Triglycerides Taking Fibrates 24
Mar 17, 2014: uniQure and Chiesi Announce Six Year Follow-up Data from Glybera Treated Patients 25
Nov 18, 2013: Isis Pharmaceuticals Reports Fifth Positive Phase 2 Data Set for ISIS-APOCIII Rx Showing Significant Reductions in Triglyceride and ApoC-III Levels 25
Sep 21, 2013: Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients with Familial Chylomicronemia 26
Jun 18, 2009: Amsterdam Molecular Therapeutics Announces New Data From Its Lead Product Glybera 27
Clinical Trial Profiles 29
Clinical Trial Overview of Top Companies 29
Novartis AG 29
Clinical Trial Overview of Novartis AG 29
Isis Pharmaceuticals, Inc. 30
Clinical Trial Overview of Isis Pharmaceuticals, Inc. 30
Aegerion Pharmaceuticals, Inc. 31
Clinical Trial Overview of Aegerion Pharmaceuticals, Inc. 31
Catabasis Pharmaceuticals, Inc. 32
Clinical Trial Overview of Catabasis Pharmaceuticals, Inc. 32
Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Inactive) 33
Clinical Trial Overview of Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Inactive) 33
Clinical Trial Overview of Top Institutes / Government 34
Charite – Universitatsmedizin Berlin 34
Clinical Trial Overview of Charite – Universitatsmedizin Berlin 34
The University of Texas Southwestern Medical Center at Dallas 35
Clinical Trial Overview of The University of Texas Southwestern Medical Center at Dallas 35
National Heart, Lung, and Blood Institute 36
Clinical Trial Overview of National Heart, Lung, and Blood Institute 36
University Hospital, Bonn 37
Clinical Trial Overview of University Hospital, Bonn 37
Five Key Clinical Profiles 38
Appendix 60
Abbreviations 60
Definitions 60
Research Methodology 61
Secondary Research 61
About GlobalData 62
Contact Us 62
Disclaimer 62
Source 62


【レポート販売概要】

■ タイトル:Familial Chylomicronemia (Type I Hyperlipoproteinemia):治療薬のグローバル治験動向(2014年上半期)
■ 英文:Familial Chylomicronemia (Type I Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2014
■ 発行日:2014年5月15日
■ 調査会社:GlobalData
■ 商品コード:GDHC2137CTIDB
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。